There is a significant amount of pre-clinical research regarding the endocannabinoid system’s (ECS) role in balancing the formation and resorption of bone.
Interestingly, when the Cannabinoid Receptor 1 (CB1) or Cannabinoid Receptor 2 (CB2) is deactivated, bone formation was favored in younger mice. However, in elderly mice, CB1 or CB2 receptor deactivation resulted in accelerated bone loss.
This makes sense as the ECS is largely devoted to maintaining homeostasis (the tendency of organisms to auto-regulate and maintain their internal environment at equilibrium).
As animals grow, bone formation is, of course, favored over resorption. Accordingly, when the ECS’ homeostatic influence was removed from young mice — via CB1 or CB2 receptor deactivation — excessive formation was the result.
However, in the elderly, bone resorption is favored over formation. Accordingly, when the ECS’ homeostatic influence was removed at this stage, accelerated bone loss was the result. These findings suggest that cannabis may be useful in slowing the progression of osteoporosis.
Based on the research above, the mechanism of action involved cannabinoids binding the CB1 and mostly CB2 receptors; THC binds the CB1 and CB2 receptors with high affinity, while CBD has very little interaction with CB1 and CB2 receptors. Therefore, I would recommend products which contain THC. However, I cannot give you specific recommendations without gathering a complete history. Please consult with a physician before starting any cannabis treatment regimen.